Related Experiment Video
Updated: Jun 2, 2026
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
Published on: July 6, 2013
Tumor-seeking Salmonella amino acid auxotrophs
1Department of Surgery, University of California, San Diego, CA 92111, USA. all@anticancer.com
Abstract:
A paradigm change in the treatment of cancer is urgently needed. Bacteria offer many advantages, including natural cytotoxity, motility, chemotaxis and a relative large genome to manipulate for tumor targeting. Salmonella, Clostridium, Bifodobacterium and Escherichia coli have been shown to control tumor growth and promote survival in animal models. We have developed an effective bacterial cancer therapy by engineering Salmonella typhimurium amino acid auxotrophs which grow in viable as well as necrotic areas of tumors, but not normal tissue. The S. typhimurium A1-R mutant, which is auxotrophic for leu-arg, is tumor-seeking and has antitumor efficacy against the major types of cancer. The approach described here is a significant improvement over previous bacterial tumor-therapy strategies that require combination with toxic chemotherapy.
Insights
Engineered Salmonella typhimurium bacteria selectively target and destroy cancer cells, offering a novel, less toxic therapy. This bacterial cancer treatment shows efficacy against major cancer types without needing chemotherapy.
Area of Science:
- Oncology
- Microbiology
- Biotechnology
Background:
- Cancer treatment requires innovative approaches beyond traditional methods.
- Bacteria possess inherent properties like cytotoxicity and tumor-homing capabilities beneficial for cancer therapy.
- Previous bacterial therapies faced limitations, often necessitating combination with toxic chemotherapy.
Purpose of the Study:
- To develop an advanced bacterial cancer therapy using engineered Salmonella typhimurium.
- To create a bacterial agent that specifically targets tumor environments, including viable and necrotic areas.
- To demonstrate antitumor efficacy independent of chemotherapy.
Main Methods:
- Engineering Salmonella typhimurium as amino acid auxotrophs (leu-arg).
- Utilizing the engineered S. typhimurium A1-R mutant for its tumor-seeking and growth properties.
- Evaluating the efficacy of the bacterial therapy against various cancer types in preclinical models.
Main Results:
- The engineered S. typhimurium A1-R mutant demonstrated tumor-specific growth in both viable and necrotic tumor regions.
- The bacteria exhibited significant antitumor efficacy against major cancer types.
- This bacterial therapy proved effective without requiring combination with toxic chemotherapy.
Conclusions:
- Engineered Salmonella typhimurium represents a promising and improved strategy for cancer treatment.
- This bacterial therapy offers a potentially safer alternative to conventional chemotherapy-based approaches.
- The tumor-seeking and cytotoxic properties of engineered bacteria hold significant potential for oncological applications.
